Franklin Resources Inc. Has $1.16 Million Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Franklin Resources Inc. grew its holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 13.4% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 30,625 shares of the specialty pharmaceutical company’s stock after acquiring an additional 3,620 shares during the quarter. Franklin Resources Inc. owned 0.09% of Collegium Pharmaceutical worth $1,164,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the stock. nVerses Capital LLC boosted its position in shares of Collegium Pharmaceutical by 1,600.0% during the second quarter. nVerses Capital LLC now owns 1,700 shares of the specialty pharmaceutical company’s stock worth $55,000 after buying an additional 1,600 shares during the period. GAMMA Investing LLC lifted its stake in Collegium Pharmaceutical by 124.5% in the 3rd quarter. GAMMA Investing LLC now owns 1,428 shares of the specialty pharmaceutical company’s stock valued at $55,000 after acquiring an additional 792 shares in the last quarter. CWM LLC lifted its stake in Collegium Pharmaceutical by 97.5% in the 3rd quarter. CWM LLC now owns 1,491 shares of the specialty pharmaceutical company’s stock valued at $58,000 after acquiring an additional 736 shares in the last quarter. TD Private Client Wealth LLC boosted its position in Collegium Pharmaceutical by 39.5% during the 3rd quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company’s stock worth $66,000 after acquiring an additional 483 shares during the last quarter. Finally, Virtus Fund Advisers LLC acquired a new stake in shares of Collegium Pharmaceutical in the third quarter valued at approximately $72,000.

Collegium Pharmaceutical Stock Down 1.3 %

Collegium Pharmaceutical stock opened at $29.11 on Friday. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88. The company’s 50-day moving average is $31.53 and its 200-day moving average is $34.18. The firm has a market capitalization of $938.80 million, a PE ratio of 12.55 and a beta of 0.80. Collegium Pharmaceutical, Inc. has a fifty-two week low of $28.75 and a fifty-two week high of $42.29.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on COLL. Piper Sandler reaffirmed a “neutral” rating and issued a $37.00 target price on shares of Collegium Pharmaceutical in a research report on Friday, October 11th. StockNews.com downgraded Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, October 23rd. Finally, HC Wainwright increased their price target on Collegium Pharmaceutical from $47.00 to $50.00 and gave the company a “buy” rating in a research report on Thursday, September 5th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $42.60.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.